
Gene Silencing Benefit of Zodasiran in Hyperlipidemia
Researchers conducted a study on the drug zodasiran, which targets a liver protein and significantly lowers triglyceride and lipoprotein levels in patients with mixed hyperlipidemia on statin therapy. The drug, an siRNA that silences the ANGPTL3 gene, showed promising results in reducing lipid levels and improving cardiovascular health. The reductions in liver fat content with…